Tay-Sachs Disease in 19 Major Markets - Forecast for 2018-2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 12, 2018--The “Epiomic Epidemiology Series: Tay-Sachs Disease Forecast In 19 Major Markets 2018-2028” report has been added to ResearchAndMarkets.com’s offering.
This report provides the current prevalent population for TSD disease across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Czech Republic, Portugal, Russia, Turkey, Saudi Arabia, Japan, China, India, Australia, Brazil) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, patients with main phenotypes and multiple symptoms of TSD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for TSD include:Visual problems Low muscle tone Seizures Neuromuscular abnormalities Speech disturbances Cerebellar dysfunctions/Impaired cognitive status.
Reasons to buyAble to quantify patient populations in global TSD market to target the development of future products, pricing strategies and launch plans. Gain further insight into the prevalence of the subdivided types of TSD and identify patient segments with high potential. Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries. Provide a level of understanding on the impact from specific co-morbid conditions on TSD prevalent population. Identify sub-populations within TSD which require treatment. Gain an understanding of the specific markets that have the largest number of TSD patients.
Key Topics Covered:Introduction Cause of the Disease Risk Factors & Prevention Diagnosis of the Disease Variation by Geography/Ethnicity Disease Prognosis & Clinical Course Key Comorbid Conditions/Features Associated With the Disease Methodology for Quantification of Patient Numbers Top-Line Prevalence for Tay-Sachs Disease Features of Tay-Sachs Disease Patients Infantile Phenotype Juvenile Phenotype Adult (LOTS) Phenotype Abbreviations Used in the Report Other Services & Solutions Reports & Publications Online Epidemiology Databases Online Pharmaceutical Pricing Database References Appendix
For more information about this report visit https://www.researchandmarkets.com/research/4pvvpt/taysachs_disease?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180712005550/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/12/2018 10:38 AM/DISC: 07/12/2018 10:38 AM